ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT), based in Lausanne, Switzerland, announced that CEO Chris Martin will speak at the Jefferies London Healthcare Conference on November 16 at 11:20 a.m. GMT. The session will be available via a live webcast on the company's website. ADC Therapeutics specializes in next-generation antibody drug conjugates for treating hematologic malignancies and solid tumors. Its FDA-approved product ZYNLONTA® is indicated for relapsed diffuse large B-cell lymphoma. The company is also developing additional ADC therapies.

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16^th at 11:20 a.m. GMT / 6:20 a.m. EST.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005902/en/

Investors

Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

+44 7879 627205

Amanda Hamilton

ADC Therapeutics

amanda.hamilton@adctherapeutics.com

+1 917-288-7023

EU Media

Alexandre Müller

Dynamics Group

amu@dynamicsgroup.ch

+41 (0) 43 268 3231

USA Media

Mary Ann Ondish

ADC Therapeutics

maryann.ondish@adctherapeutics.com

Tel.: +1 914-552-4625

Source: ADC Therapeutics

FAQ

What is ADC Therapeutics' participation in the Jefferies London Healthcare Conference?

ADC Therapeutics will have CEO Chris Martin speaking at the Jefferies London Healthcare Conference on November 16 at 11:20 a.m. GMT.

How can I watch the ADC Therapeutics presentation at the conference?

The presentation can be viewed live via webcast on ADC Therapeutics' website.

What is the focus of ADC Therapeutics as a biotechnology company?

ADC Therapeutics focuses on developing next-generation antibody drug conjugates for treating cancer.

What is ZYNLONTA® and its relevance to ADC Therapeutics?

ZYNLONTA® is an FDA-approved ADC by ADC Therapeutics for treating relapsed or refractory diffuse large B-cell lymphoma.

What type of malignancies does ADC Therapeutics target?

ADC Therapeutics targets hematologic malignancies and solid tumors with its ADC technology.